Vitruvias is a specialty generic pharmaceutical business focused on the development and marketing of generic products with either (i) complex APIs that are difficult to source, or (ii) finished dosage forms that are inherently difficult to manufacture. The highly skilled team at Vitruvias has expertise in all aspects of the pharmaceutical industry, including product development, licensing, regulatory affairs, marketing, financial analysis, distribution, managed care, trade relations and sales.
vitruvias.com.
vitruvias.com.
Location: United States, Alabama, Auburn
Total raised: $11.5M
Investors 1
| Date | Name | Website |
| - | Perceptive... | perceptive... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.01.2018 | Series A | $11.5M | Perceptive... |
Mentions in press and media 4
| Date | Title | Description |
| 09.01.2018 | Vitruvias Therapeutics Completes $11.5M Series A Financing | Vitruvias Therapeutics, Inc., an Auburn, Ala.-based generic pharmaceutical company with a focus on sterile injectables, completed a $11.5m Series A financing. The round was led by JW Asset Management LLC, and Perceptive Advisors. In conjunc... |
| 09.01.2018 | Term Sheet — Tuesday, January 9 | A DYNAMITE YEAR Good morning, Term Sheet readers. Paid Content You can't secure what you can't see From ExtraHop The U.S. venture capital industry deployed $84 billion invested in 8,035 companies across 8,076 deals, according to a new Pitch... |
| 07.01.2018 | Vitruvias Therapeutics Completes $11.5M Series A Led by JW Asset Management and Perceptive Advisors | AUBURN, Ala.--(BUSINESS WIRE)--Vitruvias Therapeutics Inc., a private generic pharmaceutical company with a focus on sterile injectables, announced today the completion of a $11.5 million Series A preferred financing. The investment was led... |
| 07.01.2018 | Vitruvias Therapeutics Completes $11.5M Series A Led by JW Asset Management and Perceptive Advisors | AUBURN, Ala.--(BUSINESS WIRE)--Vitruvias Therapeutics Inc., a private generic pharmaceutical company with a focus on sterile injectables, announced today the completion of a $11.5 million Series A preferred financing. The investment was led... |